# Transcriptomic Insights into lncRNA–miRNA–mRNA Networks Regulating Angiogenesis and Metastasis in Prostate Cancer

**Authors:** Jonathan Puente-Rivera, Stephanie I. Nuñez Olvera, Ameyatzin Ereth Robles-Chávez, Nayeli Goreti Nieto-Velázquez, María Elizbeth Alvarez-Sánchez

PMC · DOI: 10.3390/biotech15010012 · BioTech · 2026-02-01

## TL;DR

This study explores how non-coding RNAs regulate blood vessel growth and cancer spread in prostate cancer, identifying a key RNA network that could be used as a biomarker or treatment target.

## Contribution

The study identifies a novel lncRNA–miRNA–mRNA axis (LINC00261–miR-206–HIF1A) involved in prostate cancer angiogenesis and metastasis.

## Key findings

- miRNAs like hsa-miR-183-5p and hsa-miR-216a-5p are upregulated in metastatic prostate cancer and linked to pro-angiogenic signaling.
- The LINC00261–miR-206–HIF1A axis is a central regulatory module in PCa progression, validated through RT-qPCR in patient samples.
- Downregulation of LINC00261 and miR-206, along with HIF1A overexpression, is significantly associated with metastatic disease.

## Abstract

Prostate cancer (PCa) is a leading cause of cancer-related mortality in men and is often characterized by aggressive growth and bone metastasis. Angiogenesis plays a central role in tumor progression and dissemination. This study aimed to explore the regulatory roles of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in angiogenesis and metastasis during PCa progression. Publicly available RNA-seq datasets were analyzed to identify differentially expressed miRNAs between metastatic (N1) and nonmetastatic (N0) PCa. Bioinformatic tools were used to reconstruct co-regulatory networks involving miRNAs, lncRNAs, and angiogenesis-related mRNAs. RT-qPCR was performed on serum-derived liquid biopsies from N0 and N1 patients and healthy controls to validate the key regulatory axes. Transcriptomic analysis revealed that miRNAs such as hsa-miR-183-5p and hsa-miR-216a-5p were upregulated in N1 PCa and associated with pro-angiogenic signaling, whereas hsa-miR-206 and hsa-miR-184, known for their anti-angiogenic functions, were downregulated. Network analysis identified the LINC00261–miR-206–HIF1A axis as the central regulatory module. RT-qPCR validation confirmed the significant downregulation of LINC00261 and miR-206, along with HIF1A overexpression in N1 samples compared to N0 and controls (p < 0.001), supporting in silico predictions. These findings highlight the role of ncRNA-mediated regulation of PCa angiogenesis and metastasis. The LINC00261–miR-206–HIF1A axis may serve as a promising noninvasive biomarker and potential therapeutic target. The integration of computational and experimental data provides a strong rationale for the further functional validation of advanced PCa.

## Linked entities

- **Genes:** LINC00261 (long intergenic non-protein coding RNA 261) [NCBI Gene 140828], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091]
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, CYP1B1-AS1 (CYP1B1 antisense RNA 1) [NCBI Gene 285154] {aka C2orf58}, MIR182 (microRNA 182) [NCBI Gene 406958] {aka MIRN182, miRNA182, mir-182}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SOX9-AS1 (SOX9 antisense RNA 1) [NCBI Gene 400618], MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, RNU6-1 (RNA, U6 small nuclear 1) [NCBI Gene 26827] {aka RNU6, RNU6A, RP103, U6, U6-1}, MIR206 (microRNA 206) [NCBI Gene 406989] {aka MIRN206, miRNA206, mir-206}, MAGI1-IT1 (MAGI1 intronic transcript 1) [NCBI Gene 151877], MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, MMP24OS (MMP24 opposite strand) [NCBI Gene 101410538] {aka MMP24-AS1}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, VIM (vimentin) [NCBI Gene 7431], SPHK1 (sphingosine kinase 1) [NCBI Gene 8877] {aka SPHK}, FHL1 (four and a half LIM domains 1) [NCBI Gene 2273] {aka FCMSU, FHL-1, FHL1A, FHL1B, FLH1A, KYOT}, ATP2B4 (ATPase plasma membrane Ca2+ transporting 4) [NCBI Gene 493] {aka ATP2B2, MXRA1, PMCA4, PMCA4b, PMCA4x}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MIR107 (microRNA 107) [NCBI Gene 406901] {aka MIRN107, miR-107}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, MAGI1 (membrane associated guanylate kinase, WW and PDZ domain containing 1) [NCBI Gene 9223] {aka AIP-3, AIP3, BAIAP1, BAP-1, BAP1, MAGI-1}, EGLN1 (egl-9 family hypoxia inducible factor 1) [NCBI Gene 54583] {aka C1orf12, ECYT3, HALAH, HIF-PH2, HIFPH2, HPH-2}, TUG1 (taurine up-regulated 1) [NCBI Gene 55000] {aka LINC00080, NCRNA00080, TI-227H}, LINC00665 (long intergenic non-protein coding RNA 665) [NCBI Gene 100506930] {aka CIP2A-BP}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, XIST (X inactive specific transcript) [NCBI Gene 7503] {aka DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66}, MIR147B (microRNA 147b) [NCBI Gene 100126311] {aka MIRN147B, mir-147b}, LINC00482 (long intergenic non-protein coding RNA 482) [NCBI Gene 284185] {aka C17orf55}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, MIR221 (microRNA 221) [NCBI Gene 407006] {aka MIRN221, miRNA221, mir-221}, HIF1AN (hypoxia inducible factor 1 subunit alpha inhibitor) [NCBI Gene 55662] {aka FIH1}, MMP25-AS1 (MMP25 antisense RNA 1) [NCBI Gene 100507419], SPRY2 (sprouty RTK signaling antagonist 2) [NCBI Gene 10253] {aka IGAN3, hSPRY2}, KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, MIR6753 (microRNA 6753) [NCBI Gene 102465451] {aka hsa-mir-6753}, SND1 (staphylococcal nuclease and tudor domain containing 1) [NCBI Gene 27044] {aka TDRD11, TSN, Tudor-SN, p100}, PTGDR (prostaglandin D2 receptor) [NCBI Gene 5729] {aka AS1, ASRT1, DP, DP1, PTGDR1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, MIR137 (microRNA 137) [NCBI Gene 406928] {aka MIRN137, miR-137}, YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) [NCBI Gene 7534] {aka 14-3-3-zeta, HEL-S-3, HEL-S-93, HEL4, KCIP-1, POPCHAS}, ZFPM2 (zinc finger protein, FOG family member 2) [NCBI Gene 23414] {aka DIH3, FOG2, PRDM19, SRXY9, ZC2HC11B, ZNF89B}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, MIR222 (microRNA 222) [NCBI Gene 407007] {aka MIRN222, miRNA222, mir-222}, MIR34A (microRNA 34a) [NCBI Gene 407040] {aka MIRN34A, miRNA34A, mir-34, mir-34a}, HOXA-AS3 (HOXA cluster antisense RNA 3) [NCBI Gene 100133311] {aka HOXA6as}, SCARNA9 (small Cajal body-specific RNA 9) [NCBI Gene 619383] {aka Z32, mgU2-19/30}, VEGFC (vascular endothelial growth factor C) [NCBI Gene 7424] {aka Flt4-L, LMPH1D, LMPHM4, VRP}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, MIR184 (microRNA 184) [NCBI Gene 406960] {aka EDICT, MIRN184, miR-184}, LINC00261 (long intergenic non-protein coding RNA 261) [NCBI Gene 140828] {aka ALIEN, C20orf56, DEANR1, FALCOR, HCCDR1, LCAL62}, HOTAIR (HOX transcript antisense RNA) [NCBI Gene 100124700] {aka HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072}, LINC-PINT (long intergenic non-protein coding RNA, p53 induced transcript) [NCBI Gene 378805] {aka LincRNA-Pint, MKLN1-AS1, PINT, PINT87aa, TISPL}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, SEMA6A (semaphorin 6A) [NCBI Gene 57556] {aka HT018, SEMA, SEMA6A1, SEMAQ, VIA}, MIR216A (microRNA 216a) [NCBI Gene 406998] {aka MIR216, MIRN216, MIRN216A, miRNA216, mir-216, mir-216a}
- **Diseases:** hypoxia (MESH:D000860), hypoxic (MESH:D002534), metastatic (MESH:D000092182), cancer (MESH:D009369), lung cancer (MESH:D008175), glioma (MESH:D005910), PCa (MESH:D011471), injury to (MESH:D014947), prostate tumors (MESH:D011472), breast and bladder cancer (MESH:D001943), lymph node metastasis (MESH:D008207), atherosclerosis (MESH:D050197), Metastasis (MESH:D009362)
- **Chemicals:** ethanol (MESH:D000431), isopropanol (MESH:D019840), TRIzol (MESH:C411644), water (MESH:D014867), chloroform (MESH:D002725), heme (MESH:D006418)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** DU145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105), C4-2 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_4782), HBMEC — Bos taurus (Bovine), Transformed cell line (CVCL_A1BE), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12921783/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12921783/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12921783/full.md

---
Source: https://tomesphere.com/paper/PMC12921783